Q4FY17 Results: Granules India Ltd

Granules India Ltd. reported its results for the quarter ended March 31, 2017 on Thursday.

The company's total sales for Q4FY17 came in at Rs 355.25 crore, which represents a 0.75 per cent sequential increase and 4.18 per cent YoY decline.

Its operating profit (EBIT) for the quarter amounted to Rs 59.36 crore and its EBIT margin stood at 16.71 per cent.

The company reported PAT of Rs 36.28 crore, which represents a sequential QoQ increase of 1.03 per cent and a YoY increase of 2.11 per cent.

The board of directors has recommended a final dividend of Rs 0.25 per share and an interim dividend of Rs 0.65 per share on the face value of Rs 1 each for FY16-17.

Granules India Limited is a pharmaceutical company with presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). The company's business operations include three areas: core business, emerging business, and contract research and manufacturing services (CRAMS).